Bradley McEvoy, DrPH, MSc

Pimavanserin Significantly Reduces Risk of Relapse of Dementia-related Psychosis: Results From the Double-Blind Phase of the HARMONY Study

Patients with dementia often experience dementia-related psychosis (DRP), which is associated with adverse outcomes and has no approved therapy in the US. Pimavanserin is a selective sero...

Srdjan Stankovic , MD, MSPH;

Erin Foff , MD, PhD;

Bradley McEvoy , DrPH, MSc;

Jeff Cummings , MD, ScD;

Maria-Eugenia Soto-Martin , MD;

Pierre Tariot , MD;

10/08/2020

Response to Pimavanserin Treatment in Patients With Dementia-related Psychosis: Results From the 12-Week, Open-label Phase of the HARMONY Study

Dementia-related psychosis (DRP) is common in patients with Alzheimer‚Äôs disease (AD), dementia with Lewy bodies (DLB), Parkinson‚Äôs disease dementia (PDD), vascular dementia (VaD), and...

Srdjan Stankovic , MD, MSPH;

Erin Foff , MD, PhD;

Davangere Devanand , MBBS, MD;

Clive Ballard , MBChB;

Bradley McEvoy , DrPH, MSc;

10/08/2020